Daewoong Hosts Nabota Aesthetic Class in Buenos Aires
Predicted impact: Low
Daewoong대웅
003090 · KOSPI · ₩003090 · 대웅
₩14,800▲ ₩280 (1.93%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −34.51%
- Market cap
- ₩861B
- Enterprise value
- ₩963B
- P/E
- 4.8×
- P/B
- 0.7×
- Dividend yield
- 1.4%
- ROE
- 14.3%
- Net margin
- 8.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−51.6% from the high
₩14,380Today: ₩14,530 – ₩15,100₩30,600
Returns
- 1W−2.4%
- 1M−7.2%
- 3M−7.3%
- 6M−34.8%
- YTD−32.9%
- 1Y−34.5%
- Volume today
- 94,367
- 1.6× the 20-day average
- Traded today
- ₩1.4B
- Listed shares
- 58,141,980
- EPS (12 months)
- ₩3,086
- Earnings yield 20.8%
AI research · InitiationDaewoong: Shares Near 52-Week Low While Filed Profits Stay Solid and Multiples Fall Below Own HistoryThe filed numbers show a growing, profitable company with a 16.0% ROE, while the market values it at 4.8x earnings and 0.7x book, well below peers and its own recent history.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 49 of 100 (50 is a normal day for this stock).
- MomentumWeak-6.9% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Futures and options
All stock futures →Futures (2026-11): 14,910
Basis +0.74% · implied rate +18.0%
Open interest 4,875 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Daewoong stock overview
Daewoong (대웅, KRX: 003090) is listed on KOSPI, in the Biotech & Pharma sector. , Ltd. Its shares closed at ₩14,800 on Oct 28, 2026, up 1.93% on the day, giving it a market value of ₩861B.
Key facts
- Market cap
- ₩861B
- Sector
- Biotech & Pharma
- Latest price change
- +1.93%
- As of
- Oct 28, 2026
- Main business
- , Ltd.
Quick answers about Daewoong
- What does Daewoong do?
- , Ltd. is a Korean holding company that owns and manages subsidiaries in the healthcare sector, earning revenue mainly from management services, royalties and dividends from its subsidiaries and other investees. Its main subsidiaries include Daewoong Pharmaceutical, which makes and sells prescription drugs such as the botulinum toxin Nabota and the new drug Fexuclue, Daewoong Bio, which makes active pharmaceutical ingredients, and HanAll Biopharma, which develops biologic drugs, along with Daewoong Development, which provides property management services.
- What is the market cap of Daewoong?
- The market capitalisation of Daewoong was ₩861B at the close on Oct 28, 2026.
- Who are the largest shareholders of Daewoong?
- According to the latest official filings, the largest reported holders are Yoon Jae-seung (38.11%, as of May 16, 2025); National Pension Service (3.25%, as of Dec 31, 2025); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.47%, as of Jul 31, 2026).
- When is the next earnings report from Daewoong?
- Korean companies rarely announce results dates in advance. Based on when Daewoong filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Daewoong?
- Yes. The National Pension Service held 3.25% of Daewoong shares as of Dec 31, 2025.
Company profile
Daewoong Co., Ltd. is a Korean holding company that owns and manages subsidiaries in the healthcare sector, earning revenue mainly from management services, royalties and dividends from its subsidiaries and other investees. Its main subsidiaries include Daewoong Pharmaceutical, which makes and sells prescription drugs such as the botulinum toxin Nabota and the new drug Fexuclue, Daewoong Bio, which makes active pharmaceutical ingredients, and HanAll Biopharma, which develops biologic drugs, along with Daewoong Development, which provides property management services. The group operates in Korea and sells products internationally, particularly in North America.
Written by AI from the company's latest annual report.
- Korean name
- 대웅
- Sector
- Biotech & Pharma
- CEO
- 윤재춘
- Founded
- Jan 1961
- Listed
- Jun 1973
- Listed shares
- 58,141,980
- Fiscal year ends
- Month 12
- Website
- www.daewoong.com/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Daewoong eyes 2027 GMP approval for microneedle facility
Predicted impact: Low· Actual: −6.1% vs sector, volume 0.7× normal (5 trading days)
Future GMP approval target for microneedle facility; timeline far off and no size given.
Recent filings
See all- Decision on Provision of Debt Guarantee to Third Party (Material Management Matter of Subsidiary)Sep 4, 2026
- Lawsuit filed or ruledSep 2, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Major management matter relevant to investorsJul 10, 2026
- [Amendment] New Facility Investment, etc. (Major Management Matters of Subsidiary)Jun 30, 2026
Titles in Korean until English translations are added.
Also known as: Daewoong / 대웅 / 003090 / KRX:003090
Source: KRX statistical information